Name: MarketsandMarkets Next-Gen Immuno-Oncology Conference - West Coast Edition
Start: 2024-02-08
End: 2024-02-09
Location: Double Tree by Hilton, San Diego - Mission Valley | 7450 Hazard Centre Drive San Diego, CA

WHAT TO EXPECT

Latest updates on ADC’s and Bispecific Ab’s development
Immune Checkpoint Inhibitors and Combination therapies advancements
Get insights into preclinical and translational Immuno-Oncology developments, including immune checkpoint modulator preclinical models.
Biomarkers and personalized medicine in Immuno-Oncology
Potential of CAR-T Cell therapy and TCR Based-Cell Therapy
Impact of the Tumor microenvironment and Oncolytic Viruses

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

Monoclonal and Bispecific Antibodies
Cell Therapy
Immune Checkpoint Inhibitors

Discover advancements in antibodies, cellular therapy, and immune-checkpoint research all under one roof
Stay informed about the latest case studies on ongoing immune oncology projects
Engage in interactive roundtables with your peers to discuss and explore relevant topics in-depth
Explore cutting-edge platforms and technologies available for development in the field
Exchange insights and discuss the optimal research tools for immune oncology studies
Showcase your work and accomplishments to industry peers in the Poster Session

CONFERENCE AGENDA

Registration	08:10 - 09:05
Welcome note from MarketsandMarkets	09:05 - 09:10
Opening Remarks from the Chairperson Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	09:10 - 09:15
NEW ANTIBODIES DEVELOPMENT AND TUMOR MICRO-ENVIRONMENT
Keynote Presentation – Identification of potential patient selection biomarkers for the treatment of cancer with tivumecirnon (FLX475) in combination with anti-PD-1 Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	09:15 - 09:50
Nu.Q® Discover – Quantitative nucleosome biomarker profiling of the tumour microenvironment Mark Eccleston, Founder and Chief Technology Officer, Volition Eric Ariazi, Distinguished Translational Medicine Scientist, Volition	09:50 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:20
Case Studies Leveraging 20,000 Digitized IO KM Curves– Interactive Analysis and Real-Time Insights at the Forefront of Immuno-Oncology Bruno Larvol, Founder & CEO, LARVOL	11:20 - 11:55
Advancing the Immuno-Oncology Pipeline with Humanized Mice Dan Georgess, Chief Scientific Officer, TransCure bioServices,	11:55 - 12:30
Veracyte Biopharma Services, your trusted partner for biomarker testing for spatial proteomics, transcriptomics, and genomics Valerie Balme, Associate Director, Business Development, Veracyte	12:30 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:20
BioMice: Preclinical Oncology/Immuno-Oncology Models for Evaluating Novel Therapeutics in Vivo Jay Zhang, Sr. Business Development Manager, Biocytogen	14:20 - 15:00
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	15:00 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Engineered nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects. A. C. Matin, Professor of Microbiology & Immunology, Emeritus , Stanford University School of Medicine	16:30 - 17:00
Closing Remarks from the Chairperson Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	17:00 - 17:00
Drinks Reception & Networking
End of Day 1	17:00 - 17:00

Registration	08:15 - 09:00
Welcome note from MarketsandMarkets	09:00 - 09:05
Opening Remarks from the Chairperson Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics	09:05 - 09:10
PRECLINICAL AND TRANSLATIONAL IMMUNO-ONCOLOGY UPDATES- NEW CHECKPOINTS FOR IO
Rapid discovery and screening of truly human biologics Wyatt McDonnell, Co-Founder, CEO, and Chairman of the Board of Directors, Infinimmune	09:10 - 09:45
Mechanistic insights into PD-1 action-translational and clinical data. Adil Daud, Director, Melanoma Program, UCSF Medical Center	09:45 - 10:20
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:20 - 11:05
Spatial Analytics of the TME and Discovering Spatial Biomarkers for Immunotherapy Arvind Rao, Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor	11:05 - 11:40
Developments in car-t and t-cell therapies personalized immunotherapy Preclinical Data for Novel Oncolytic Agent and its Ability to Pair with Immune Checkpoint Blockade Matt Giacalone, CEO, Vaxiion Therapeutics	11:40 - 12:15
Panel Discussion: Clinical Applications of Biomarkers in Immuno-Oncology, Immunology, Neurology, and Inflammatory Diseases Jack Chen, Scientific Director, Immuno-Oncology, Precision Medicine, AbbVie Rob Fraser, Chief Scientific Officer, Molecular You Wyatt McDonnell, Co-Founder, CEO, and Chairman of the Board of Directors, Infinimmune	12:15 - 13:00
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:00 - 13:00
END OF CONFERENCE	13:00 - 13:00

SPEAKERS

Mikael Barmore

VP Biopharma Business Development, Veracyte

Arvind Rao

Associate Professor of Computational Medicine and Bioinformatics, Department of Computational Medicine and Bioinformatics, University of Michigan Ann Arbor